Skip to Content

BioLineRx Ltd.

Securities Class Action

  • Date:
  • 1/8/2023
  • Company Name:
  • BioLineRx Ltd.
  • Stock Symbol:
  • BLRX
  • Class Period:
  • FROM 2/23/2021 TO 9/19/2022
  • Status:
  • Filed
  • Filing Date:
  • 1/5/2023
  • Court:
  • U.S. District Court: District of New Jersey

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against BioLineRx Ltd. (“BioLineRx” or the “Company”) (NASDAQ: BLRX) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired BioLineRx securities between February 23, 2021 and September 19, 2022, both dates inclusive (the “Class Period”). Investors have until March 6, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things, that: (1) the Company was not well financed to develop Motixafortide while at the same time advancing other pipeline programs; (2) BioLine would require a loan from Kreos Capital VII Aggregator SCSP in an aggregate principal amount of up to $40 million and then also would require a $15M securities offering to facilitate the commercial launch of Motixafortide; and (3) as a result of the foregoing, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
 
When the truth emerged, the lawsuit claims that investors suffered damages.
 
If you purchased or otherwise acquired BioLineRx shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in BioLineRx Ltd.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: